Anti-AIDS agents 84. Synthesis and anti-human immunodeficiency virus (HIV) activity of 2'-monomethyl-4-methyl- and 1'-thia-4-methyl-(3'R,4'R)-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (DCK) analogs. 2010

Shi-Qing Xu, and Xin Yan, and Ying Chen, and Peng Xia, and Keduo Qian, and Donglei Yu, and Yi Xia, and Zheng-Yu Yang, and Susan L Morris-Natschke, and Kuo-Hsiung Lee
Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China.

In a continuing investigation into the pharmacophores and structure-activity relationship (SAR) of (3'R,4'R)-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (DCK) as a potent anti-HIV agent, 2'-monomethyl substituted 1'-oxa, 1'-thia, 1'-sulfoxide, and 1'-sulfone analogs were synthesized and evaluated for inhibition of HIV-1 replication in H9 lymphocytes. Among them, 2'S-monomethyl-4-methyl DCK (5a)(‡) and 2'S-monomethyl-1'-thia-4-methyl DCK (7a) exhibited potent anti-HIV activity with EC(50) values of 40.2 and 39.1 nM and remarkable therapeutic indexes of 705 and 1000, respectively, which were better than those of the lead compound DCK in the same assay. In contrast, the corresponding isomeric 2'R-monomethyl-4-methyl DCK (6) and 2'R-monomethyl-1'-thia-4-methyl DCK (8) showed much weaker inhibitory activity against HIV-1 replication. Therefore, the bioassay results suggest that the spatial orientation of the 2'-methyl group in DCK analogs can have important effects on anti-HIV activity of this compound class.

UI MeSH Term Description Entries
D007783 Lactones Cyclic esters of hydroxy carboxylic acids, containing a 1-oxacycloalkan-2-one structure. Large cyclic lactones of over a dozen atoms are MACROLIDES. Lactone
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D002164 Camphor A bicyclic monoterpene ketone found widely in plants, especially CINNAMOMUM CAMPHORA. It is used topically as a skin antipruritic and as an anti-infective agent. Camphor, (+-)-Isomer,Camphor, (1R)-Isomer,Camphor, (1S)-Isomer
D004261 DNA Replication The process by which a DNA molecule is duplicated. Autonomous Replication,Replication, Autonomous,Autonomous Replications,DNA Replications,Replication, DNA,Replications, Autonomous,Replications, DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D018360 Crystallography, X-Ray The study of crystal structure using X-RAY DIFFRACTION techniques. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) X-Ray Crystallography,Crystallography, X Ray,Crystallography, Xray,X Ray Crystallography,Xray Crystallography,Crystallographies, X Ray,X Ray Crystallographies

Related Publications

Shi-Qing Xu, and Xin Yan, and Ying Chen, and Peng Xia, and Keduo Qian, and Donglei Yu, and Yi Xia, and Zheng-Yu Yang, and Susan L Morris-Natschke, and Kuo-Hsiung Lee
December 2004, Bioorganic & medicinal chemistry letters,
Shi-Qing Xu, and Xin Yan, and Ying Chen, and Peng Xia, and Keduo Qian, and Donglei Yu, and Yi Xia, and Zheng-Yu Yang, and Susan L Morris-Natschke, and Kuo-Hsiung Lee
December 2004, Bioorganic & medicinal chemistry,
Shi-Qing Xu, and Xin Yan, and Ying Chen, and Peng Xia, and Keduo Qian, and Donglei Yu, and Yi Xia, and Zheng-Yu Yang, and Susan L Morris-Natschke, and Kuo-Hsiung Lee
June 2004, Bioorganic & medicinal chemistry letters,
Shi-Qing Xu, and Xin Yan, and Ying Chen, and Peng Xia, and Keduo Qian, and Donglei Yu, and Yi Xia, and Zheng-Yu Yang, and Susan L Morris-Natschke, and Kuo-Hsiung Lee
June 1998, Bioorganic & medicinal chemistry letters,
Shi-Qing Xu, and Xin Yan, and Ying Chen, and Peng Xia, and Keduo Qian, and Donglei Yu, and Yi Xia, and Zheng-Yu Yang, and Susan L Morris-Natschke, and Kuo-Hsiung Lee
June 2010, Bioorganic & medicinal chemistry,
Shi-Qing Xu, and Xin Yan, and Ying Chen, and Peng Xia, and Keduo Qian, and Donglei Yu, and Yi Xia, and Zheng-Yu Yang, and Susan L Morris-Natschke, and Kuo-Hsiung Lee
August 1998, Bioorganic & medicinal chemistry letters,
Shi-Qing Xu, and Xin Yan, and Ying Chen, and Peng Xia, and Keduo Qian, and Donglei Yu, and Yi Xia, and Zheng-Yu Yang, and Susan L Morris-Natschke, and Kuo-Hsiung Lee
January 2004, Journal of medicinal chemistry,
Shi-Qing Xu, and Xin Yan, and Ying Chen, and Peng Xia, and Keduo Qian, and Donglei Yu, and Yi Xia, and Zheng-Yu Yang, and Susan L Morris-Natschke, and Kuo-Hsiung Lee
March 2001, Journal of medicinal chemistry,
Shi-Qing Xu, and Xin Yan, and Ying Chen, and Peng Xia, and Keduo Qian, and Donglei Yu, and Yi Xia, and Zheng-Yu Yang, and Susan L Morris-Natschke, and Kuo-Hsiung Lee
May 2000, Bioorganic & medicinal chemistry letters,
Shi-Qing Xu, and Xin Yan, and Ying Chen, and Peng Xia, and Keduo Qian, and Donglei Yu, and Yi Xia, and Zheng-Yu Yang, and Susan L Morris-Natschke, and Kuo-Hsiung Lee
September 2001, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!